UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 1, 2026

Gyre Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**000-51173**	**56-2020050**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12730 High Bluff Drive **Suite 250** **San Diego, CA**	**92130**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(858) 284-0115**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	GYRE	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On June 1, 2026, Gyre Therapeutics, Inc. (the "Company") made available an updated corporate presentation on the Company's website.

A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits*.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Corporate Presentation, dated June 2026
104	Cover page interactive data file (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GYRE THERAPEUTICS, INC.

Date: **June 2, 2026**

By: /s/ Thomas Eastling
Name: Thomas Eastling
Title: Chief Financial Officer

Exhibit 99.1

A Fully-Integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory Diseases and Cancer

Gyre THERAPEUTICS

Forward-looking Statements

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the current plans, expectations and strategies of Gyre Therapeutics, Inc. ("Gyre") and its subsidiaries, including Cullgen Inc. ("Cullgen"), which statements are subject to substantial risks and uncertainties and are based on management's estimates and assumptions. All statements, other than statements of historical facts included in this presentation, are forward-looking statements, including Gyre's ability to leverage China operations for discovery, validation and development of therapeutics, clinical development plans, anticipated timelines and milestones of CG923308, F528, CG620953, F351, CG001419, CG009301, and ETUARY™, including anticipated regulatory submissions and approvals, and the potential therapeutic benefits, efficacy, safety and differentiation of such product candidates, and market size and commercial opportunity estimates. Gyre or Cullgen's plans, objectives, goals, strategies, future events, or intentions relating to Gyre or Cullgen's products and markets, the safety, efficacy and clinical benefits of Gyre or Cullgen's product candidates, the anticipated timing and design of any planned and ongoing preclinical studies and clinical trials, Gyre or Cullgen's research and development efforts, plans and objectives of management for future operations and future results of anticipated product development efforts, potential addressable market size and Gyre or Cullgen's liquidity and capital resources and business trends. In some cases, you can identify forward-looking statements by terms such as "believe," "can," "could," "anticipate", "design," "estimate," "expect," "forecast," "intend," "may," "might," "plan," "target", "potential," "predict," "objective," "should," "strategy," "will," "would," "forthcoming," or the negative of these terms, and similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements may include express or implied statements relating to: the estimated future financial performance and financial position of Gyre; the synergies that may be achieved between Gyre and Cullgen; the therapeutic potential and utility, efficacy and clinical benefits of the product candidates of the combined company, including for the treatment of fibrosis, pain and solid tumors; the risk/benefit profile of the product candidates of the combined company; expectations regarding Gyre or Cullgen's research and development efforts, including timing of initiation of Phase 2 trials for the product candidates of the combined company; Gyre or Cullgen's expectations regarding the advancement of product candidates into IND-enabling studies; and Gyre and Cullgen's expectations, hopes, beliefs, intentions and strategies; and other statements that are not historical fact. These statements involve known and unknown risks, uncertainties and other factors that could cause Gyre or Cullgen's actual results to differ materially from the forward-looking statements expressed or implied in this presentation, in addition to those risks and uncertainties, such as the uncertainties inherent in the clinical drug development process, the regulatory approval process, the timing of any regulatory filings, the potential for substantial delays, the risk that earlier study results may not be predictive of future study results, manufacturing risks, competition from other therapies or products and the impacts of current macroeconomic and geopolitical risks. A discussion of these and other factors, is set forth in Gyre's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the "SEC") on March 13, 2026 and elsewhere in such other filings and in Gyre's periodic reports and subsequent disclosure documents filed with the SEC. Each of Gyre and Cullgen cannot assure you that it will realize the results, benefits or developments that it expects or anticipates or, even if substantially realized, that they will result in the consequences or affect Gyre or Cullgen or its business in the way expected. Forward-looking statements are not historical facts and reflect management's current views with respect to future events. Given the significant uncertainties, you should evaluate all forward-looking statements in the context of these risks and uncertainties and not place undue reliance on these forward-looking statements as predictions of future events. All forward-looking statements in this presentation apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this presentation. Gyre and Cullgen have no intention to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Certain information contained in this presentation and statements made orally during this presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and Gyre or Cullgen's own internal estimates and research. While each of Gyre and Cullgen believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent sources have evaluated the reasonableness or accuracy of Gyre or Cullgen's internal estimates or research, and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research. This presentation contains, trademarks, trade names and service marks of other companies which are the property of their respective owners. This presentation concerns a discussion of investigational drugs that are under preclinical and/or clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.

Gyre Therapeutics (Nasdaq: GYRE): At-A-Glance

Following Recent Acquisition of Cullgen

Pipeline ranges from discovery stage to marketed products with programs covering multiple therapeutic areas including fibrosis, inflammatory diseases and cancer

~740 Employees WW

- ~170 R&D
- ~85 Manufacturing
- ~370 Sales & Marketing
- ~115 G&A

Combined entity intends to **leverage established and cost-efficient China operations** for accelerated discovery, early validation, and development of next generation therapeutics based on degraders and DACs

San Diego, CA
Corporate HQ
- G&A, Clinical Development

Beijing, China
Manufacturing, Clinical Development and Commercialization

Shanghai, China
Drug Discovery, Clinical Development

Gyre THERAPEUTICS

Fibrosis, Inflammatory Diseases, Cancer Portfolio Based on US-China Innovation

IND Enabling	Phase 1	Phase 2	Phase 3	NDA Filed	Marketed
CG620953 TYK2/JAK1 Degrader for Inflammatory Diseases	**F351 (hydronidone)** MASH-Associated Liver Fibrosis		**ETUARY™ (pirfenidone)** Pneumoconiosis Line Extension	**F351 (hydronidone)** CHB-associated Liver Fibrosis	**ETUARY™ (pirfenidone)** Idiopathic Pulmonary Fibrosis (IPF)
CG923308 CDK2/Cyclin E Degrader for Solid Cancers			**ETUARY™ (pirfenidone)** Radiation Induced Lung Injury (Phase 2/3) Line Extension		
F528 Chronic Obstructive Pulmonary Disease (COPD)					

Degrader

China Innovation and Validation Engine: **Driving Strategic Value and Efficiency**



Efficient and cost-effective operations accelerate new pipeline development and indication expansion

Gyre THERAPEUTICS

Gyre's ETUARY™ is the Market Leader of Pirfenidone for Treatment of Organ Fibrosis

First Product ETUARY™ Demonstrates Gyre's Capability from Innovation to Commercialization and Managing Life Cycle of Innovative Drugs



Upcoming line extensions for ETUARY™ are expected to catalyze sales growth

Third party pirfenidone sales outside of China fell substantially during same period and never recovered due to generic competition.

Gyre THERAPEUTICS

Promising Preclinical and Clinical Results for Two ETUARY™ Line Extensions
Potential to Drive Market Expansion

A. Preclinical studies demonstrate efficacy of Etuary™ in treating pneumoconiosis[1]





B. A phase 2 trial demonstrates efficacy of Etuary™ in treating radiation-induced lung injury (RILI)[2]



Gyre THERAPEUTICS

Ref 1. Bai et al. (2025) https://pubmed.ncbi.nlm.nih.gov/39546810/
Ref 2. Hou et al (2025) https://pubmed.ncbi.nlm.nih.gov/41207313/

BIBF: nintedanib; DLCO: Diffusing Capacity of the Lung for Carbon Monoxide ; IC: Inspiratory Capacity; FEV: Forced Expiratory Volume; FVC: Forced Vital Capacity; PFD: Pirfenidone; Si: Silicosis

F351 (hydronidone) A Next Generation Liver Fibrosis Therapy

F351 (hydronidone): An NDA Stage Next-Generation Fibrosis Therapy

Primary Indication	Liver fibrosis caused by Chronic Hepatitis B (CHB) and Metabolic dysfunction-Associated Steatohepatitis (MASH)
Summary	Next-Generation Pirfenidone: An Antifibrotic Agent with Enhanced Potency, Improved Safety, and Favorable Metabolism.
Clinical Rationale	F351 modulates the Smad7-TGF-β and p38γ signalling pathways, preventing the activation of hepatic stellate cells (HSCs)—the primary drivers of collagen deposition and fibrotic scarring in the liver. ***F351 will be positioned as a complementary therapy to agents targeting metabolic drivers of fibrosis such as agonists of GLP-1 and THR-β receptors and FGF21 analog.***
Current Status	Phase 3 trial of CHB-associated liver fibrosis was completed in China; Last patient completed treatment Oct 2024; Reported positive topline data in Q2 2025 — met primary endpoint. NDA accepted by NMPA in May 2026
Regulatory	Breakthrough Therapy designation from NMPA (March 2021) for CHB-induced liver fibrosis by NMPA and CDE. U.S. IND for MASH filed, with anticipated Phase 2 start in 2027.
Opportunity	China: Largest burden of hepatitis B world-wide, with an estimated 79 – 86 million cases of chronic HBV infections[1] USA: 14.9 million MASH patients in 2020 and increases to 23.2 million by 2050[2]

F351 Upregulates Smad7, Downregulates TGF-β receptor I, and Reduces Collagen Secretion[3,4]



F351 Development Highlights

Phase 1 China & USA	✓ Well tolerated as a single agent and upon repeated oral dosing, with no SAEs reported. ✓ Consistent safety and PK profile in US trial
Phase 2 China	✓ Met primary endpoint of improvement of liver fibrosis score (Ishak decrease of ≥1 point) ✓ Good tolerability ✓ The 90 mg/tid dose selected for Phase 3
Phase 3 China	✓ Positive Phase 3 topline results in CHB-associated liver fibrosis. ✓ NDA accepted by China NMPA in May 2026

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11806133/
2. https://pubmed.ncbi.nlm.nih.gov/39821400/
3. Xu et al (2023) PMID:37641479
4. Internal unpublished results

F351 Phase 3 Results Demonstrate New Global Potential in Liver Fibrosis and Cirrhosis

Breakthrough Therapy Designation
Priority Review of NDA
(China NMPA, 2021, 2026)

NDA accepted by NMPA in May 2026

Primary Endpoint Met with High Statistical Significance

≥1-stage fibrosis regression at Week 52:

- F351: 52.85% (n=123) vs.
- Placebo: 29.84% (n=124)
- **Delta: 23.01%**
- **p = 0.0002** (ITT[1] analysis with central blinded pathology review)
- Consistent with fibrosis regression rates observed in Phase 2

Key Secondary Endpoint Reduction in Liver Inflammation

≥1-grade inflammation improvement without fibrosis progression at Week 52:

- F351: 49.57% (n=123) vs.
- Placebo: 34.82% (n=124)
- **Delta: 14.75%**
- **p = 0.0246**
- Reinforces anti-inflammatory activity

Favorable Safety Profile

≥1-stage fibrosis regression at Week 52:

- F351: 52.85% (n=123) vs.
- Placebo: 29.84% (n=124)
- **Delta: 23.01%**
- **p = 0.0002** (ITT1 analysis with central blinded pathology review)
- Consistent with fibrosis regression rates observed in Phase 2

U.S. MASH Fibrosis Market Provides Significant Opportunity for F351

China First Strategy Provides Accelerated POC

Forecasted Market Size of MASH Fibrosis Therapies in the USA ($M USD)



- Current U.S. MASH prevalence is estimated at ~14 million[1]
- MASH represents tremendous growth opportunity due to very low current MASH diagnosis rate (5-10%)
- Rising obesity and diabetes increase MASH progression via liver inflammation

Gyre THERAPEUTICS

USA MASH Therapeutics Sales forecast from Evaluate Pharma as of 5-13-2026
Assumes 50% of all MASH patients progress to MASH fibrosis (Stage ≥ F2) based on Luthra & Sheth (2025).
1 Le et al. (2025) JAMA; AJMC; MASH Awareness; Estes et al. (2018) AASLD; L.E.K. interviews

Promising Path for Future Growth:

Targeted Protein Degraders (TPDs) and Degrader-Antibody Conjugates (DACs) Pipeline

- CDK2 - Cyclin E Dual-Degrader for Solid Tumors
- TYK2 - JAK1 Dual-Degrader for Inflammatory Diseases

CDK2 - Cyclin E Dual-Degrader for Solid Tumors

Hyperactivation of the CDK2–Cyclin E Complex Drives Solid Tumor Progression and Confers Resistance to Breast Cancer Therapy

A. CDK2-cyclin E promotes cell proliferation and cancer development



Cell proliferation

Cancer development

CDK2-cyclin E dual degrader blocks feedback induction of cyclin E by CDK2 inhibition and achieves sustained suppression of cell proliferation

B. Cyclin E is frequently amplified across multiple cancer types



Analyzed by cbioportal (TCGA, PanCancer)

D. Diverse CDK4/6i resistance converge on activation of CDK2/cyclin E



[1] Turner NC (2019) *J Clin Oncol*. PMID: 30807234
[2] Herrera-Abreu MT (2016) *Cancer Res*. PMID: 27020857
[3] Costa C (2020) *Cancer Discov*. PMID: 31594766
[4] Freeman-Cook (2021) *Cancer Cell*. PMID: 34520734
[5] Wander SA (2020) *Cancer Discov*. PMID: 32404308

C. Elevated cyclin E1 and E2 expression correlates with poor patient survival and therapy resistance

CCNE1 amplification correlates with poor survival in ovarian cancer patients[1]



CCNE2 overexpression correlates with resistance to endocrine therapy in breast cancer[2]



High CCNE1 expression is associated with resistance to CDK4/6 inhibitor in breast cancer[3]



1. TCGA (2011) *Nature* PMID: 21720365; 2. Milioli et al. (2020) *Endocr Relat Cancer* PMID: 32061162; 3. Freeman-Cook (2021) *Cancer Cell* PMID: 34520734

Gyre THERAPEUTICS

CDK2-Cyclin E Degrader for Treating *CCNE1*-amplified Solid Tumors and Breast Cancer Resistant to CDK4/6 Inhibitors; IND Anticipated Q1 2027

A. Deletion of CDK2/E1 re-sensitizes CDK4/6i-resistant cells to CDK4/6i[1,2]





1. Freeman-Cook (2021) *Cancer Cell* PMID: 34520734; 2. Herrera-Abreu et al (2016) *Cancer Res* PMID: 27020857

C. Discovery of selective CDK2 - cyclin E dual degraders



B. Target product profile

Indication	Solid tumors with *CCNE1* amplification (CCNE1^{amp}); HR+/HER2- breast cancer with CDK4/6i resistance;
Patient Population	Estimated in the US for 2024 by ACS (cancer.org) and cbioportal analysis of TCGA database **CCNE1^{amp} solid cancer: >25,000 new cases/year** • Ovarian cancer (19,680 new cases, 19% CCNE1^{amp}) • Endometrial cancer (67,880 new cases, 10.8% CCNE1^{amp}) • TNBC (62,144 new cases, 10.7% CCNE1^{amp}) • Esophagogastric cancer (49,260 new cases, 10.1% CCNE1^{amp}) • Non-small-cell lung cancer (187,664 new cases, 4% CCNE1^{amp}) **HR+HER2- metastatic breast cancer with CDK4/6i resistance: ~25,000 patients/year** • (310,720 new cases of breast cancer, 73% are HR+, 20-30% with metastatic disease; 40-50% progression rate)
Current SOC (US)	• Chemotherapy/ADCs • Hormone therapy (ovarian, breast) • Immunotherapy (breast, esophagogastric) • Targeted therapy (e.g. CDK4/6i, HER2 mAb, PARPi)
Unmet Clinical Needs	• Chemo/ADCs/hormone/targeted therapy: drug resistance, side effects • Immunotherapy: low response rate as monotherapy
Clinical Position	• Solid tumors with CCNE1^{amp} • Breast cancer with CDK4/6i resistance
Biomarker	• CCNE1^{amp} • CDK4/6i resistant
Proof-of-concept Study	Phase 1a/1b with expansion cohorts in CCNE1^{amp} ovarian, endometrial, TNBC, esophagogastric cancer as monotherapy; Phase 1a/1b with expansion cohorts in CDK4/6i resistant HR+ breast cancer as monotherapy;

Gyre THERAPEUTICS

CDK2-Cyclin E Degrader Demonstrates Greater *In Vivo* Anti-Cancer Efficacy Than Phase 2/3 CDK2 Inhibitors in CDX and PDX Models

A. *CCNE1*-amp OVCAR3 Ovarian CDX



B. *CCNE1*-amp MKN1 Gastric CDX



C. *CCNE1*-amp HCC1599 TNBC CDX



D. *CCNE1*-amp HCC1569 Breast CDX



E. Chemo-resistant *CCNE1*-amp TNBC PDX



F. *Rb*-deficient, CDK4/6i-resistant Breast PDX



All doses were well tolerated in animals, with no significant body weight loss observed during the studies

TYK2 - JAK1
Dual-Degrader
for Inflammatory Diseases

Dual Targeting of TYK2 and JAK1 for Autoimmune Diseases, Focus on Systemic Lupus Erythematosus and Rheumatoid Arthritis

A. TYK2/JAK - STAT signaling



Platanias, LC. (2005) *Nat Rev Immunol* PMID:15864272

B. SLE Mechanism



Tsokos GC.(2011) *NEJM* PMID: 22129255

C. RA Mechanism



McInnes & Schett (2011) *NEJM* PMID: 22150039

Significant Opportunity

- 125,000,000 psoriasis patients worldwide[1]
- 18,000,000 rheumatoid arthritis patients worldwide[2]
- ~204,000 lupus patients in the US in 2018[3]

1. https://www.psoriasis.org/psoriasis-statistics/
2. https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis
3. https://www.niams.nih.gov/health-topics/lupus/basics/symptoms-causes

Gyre THERAPEUTICS

CG620953 Demonstrates Superior Efficacy in Preclinical Models of Lupus and Rheumatoid Arthritis (RA)

A. CG620953 is effective in a mouse model of systemic lupus erythematosus (SLE)







B. CG620953 shows efficacy in a rat model of rheumatoid arthritis





C. Targeted protein degradation in RA model



Gyre THERAPEUTICS

Leveraging China Innovation Advantages to Advance Pipeline Products

Gyre's China Innovation and Validation Engine Provides Ability to Leverage China's Unique Ecosystem Pillars



1. ARC Group Insights – July 21, 2025
2. Comparison vs. Boehringer Ingelheim nerandomilast phase 3 study

Degraders for Cancer and Cancer-induced Bone Pain
- TRK degrader (CG001419)
- GSPT1 degrader (CG009301)

Targeting TRK for Pain and Cancer

A. TRK signaling pathways



B. Activation of TRK in multiple solid tumors



Gyre THERAPEUTICS

Cocco, Scaltriti & Drilon (2018) *Nat Rev Clin Oncol* PMID: 30333516

Clinical Development of CG001419 for Cancer



Future Data Points

- Data from first 22 patients demonstrated no observed DLTs, treatment-related SAEs or grade ≥3 treatment related AEs.
- Enrollment in Phase 1b (dose expansion portions) began Q1 2026.

Summary of CG001419 for Cancer

1 Positioning and Differentiation

- First-in-Class, selective, oral TRK degrader for the treatment of adult cancer patients with NTRK gene abnormalities
- Potential use in cancer patients with NTRK gene fusion who acquire resistance to prior TRK kinase inhibitors via NTRK mutations

2 Clinical Strategy

- Exploratory study in cancer patients with NTRK amplification, overexpression and point mutations

3 Clinical Development Plan

A rational, step-wise, biomarker-driven Phase 1/2 study design with expansion cohorts to provide early efficacy readout and assess the safety, PK and PK/PD relationships in selected tumors

- If successful, expected accelerated regulatory pathway toward early approval, including breakthrough designation
- Early incorporation of biomarker strategy supports development of precision treatment and associated companion diagnostic (CDx)

NGF And TRK Are Key Mediators of Acute and Chronic Pain

A. Nerve growth factor (NGF) stimulates the TrkA signaling pathway to transmit pain to the central nervous system



Injury / Inflammation | NGF-TRKA complex | Dorsal root ganglion (DRG) | Brain

B. TRKA mutations cause congenital insensitivity to pain and anhidrosis (CIPA)

Sequencing of a cohort 78 CIPA patients

Mutations identified in:	22 genes
Mutation in *TRKA*:	20 patients
Mutation in *NGF*:	2 patients
Mutation in *Nav1.7*:	22 patients
Other 19 genes:	34 patients

Indo et al (1996) *Nat Genet*. PMID: 8696348
Lischka et al (2023) *Brain* PMID: 37769650



C. Blocking NGF reduces cancer bone pain



Fallon et al. (2023) *Oncologists* PMID: 37343145

Gyre THERAPEUTICS

Summary of Phase 1 PD, PK and Safety Study of CG001419

CG001419-101 (NCT06636500): a SAD/MAD/FE study in healthy subjects in Australia

- The surrogate PD assay demonstrated DC_{50} and DC_{90} values of 2.4 nM and 18.2 nM, respectively
- Single and multiple oral doses of CG001419 up to the highest dosing levels were safe and well tolerated by the healthy subjects
- In the SAD/FE of the study, 72.2% had a TEAE and in the MAD 83.9% had a TEAE
- Most TEAEs were considered mild or moderate at their maximum severity in both parts of the study. No Grade 4 (potentially life-threatening) TEAEs were reported
- The most frequently reported TEAEs by SOC were general disorders and administration site conditions. Since the drug was administered orally, these were likely due to blood collection procedures
- Following a single oral dose, the exposure to CG001419 increased in a dose-proportional manner
- The food-effect cohort demonstrated a higher systemic exposure under the fed condition
- For the MAD cohorts after multiple daily dosing for 7 days, exposure to CG001419, metabolite M2 and M8 increased in a less than dose-proportional manner







Gyre THERAPEUTICS

CG001419: Differentiated as a Potential First in Class Non-Opioid Medicine for the Treatment of Pain

	Opioids	NSAIDs	Cebranopadol (Tris Pharma)	Journavx (Suzetrigine, VX-548) (Vertex)	VX-993 (Vertex)	LTG-001 (Latigo Bio)	STC-004 (SiteOne Therapeutics / Lilly)	CG001419 (Gyre Therapeutics)
Safety Concerns	Risk to develop dependency	GI issues, headache, dizziness	Nausea	–	–	–	–	–
Effective	✓	Moderate	Moderate	Moderate	Did not meet acute pain primary endpoint	TBD	TBD	✓ Preclinical studies
MOA	Neuron hyperpolarization	COX inhibitor	Dual-NMR (NOP and opiate receptor) agonist First-in-class	Nav1.8 inhibitor First-in-class	Nav1.8 inhibitor Fast-follower	Nav1.8 inhibitor Fast-follower	Nav 1.8 inhibitor Fast-follower	TRK degrader First-in-class
Non-addictive	Rapid development (< 5 – 14 days)	✓	TBD	✓	✓	✓	✓	✓
Phase	Approved	Approved	Phase 3 Trials Complete	Approved	Discontinued as monotherapy for acute pain	Phase 1 Complete	Phase 1 Complete	Phase 1 Complete

Cancer-induced Bone Pain Market Opportunity

Current pharmacological therapies to treat CIBP are inadequate, with 70% treated with opioids reporting continued bone pain[1]

Tanezumab, an NGF antibody, showed reduction in pain in phase III trials of cancer patients with bone pain[2]

Opioids – Marginally effective at relieving CIBP and come with significant side-effects (nausea, vomiting, constipation) especially for advanced or palliative stage cancer patients where quality of life is paramount



1. https://pubmed.ncbi.nlm.nih.gov/30627511
2. https://pubmed.ncbi.nlm.nih.gov/37343145
3. https://pubmed.ncbi.nlm.nih.gov/22570568
4. https://pubmed.ncbi.nlm.nih.gov/26229504
4. https://pubmed.ncbi.nlm.nih.gov/23344095
6. https://pubmed.ncbi.nlm.nih.gov/25919474
7. https://pubmed.ncbi.nlm.nih.gov/37343145
8. Estimates based on treatment pricing of $10 / day

Summary of CG001419 for Pain

1 Positioning and Differentiation

- First-in-class TRK degrader as an analgesic for acute and chronic pain
- Potential for differentiation in efficacy and safety from NSAIDs, opioids, and NAV1.8 inhibitors via novel mechanism of action

2 Clinical Strategy

- Rational, mechanism-based selection of indications and target populations
- Planned Phase 2 study in cancer-induced bone pain applications
- Objectives:
  1) magnitude and time course of CG001419 analgesia relative to placebo
  2) safety of CG001419 compared to placebo
  3) PK characteristics of CG001419

3 Clinical Development Plan

- Phase 1a trial in Australia to assess PK and safety completed Q4 2025
- Phase 2 POC trial in patients with cancer-induced bone pain or other metastatic cancer pain syndromes

Targeting GSPT1 for AML and MYC+ Cancers

- GSPT1 controls protein translation termination and plays important function for leukemia stem cells and tumor cells with MYC overproduction.
- GSPT1 lacks an active site and is often considered “undruggable”.
- Cullgen has developed a potent and selective GSPT1 degrader, CG009301.
- Preclinical studies have validated the selectivity, potency and safety of CG009301.





US Patient Population

AML[1]	MDS[1]	ALL[1]	MYC-amplified solid tumors[2,3]
~20,800 new cases	**~10,000** new cases	**~6,500** new cases	**28%**
11,220 mortality	30-40% MDS progress to AML[4]	**1,330** mortality	

[1] 2024 by American Cancer Society estimates
[2] The Cancer Genome Atlas (TCGA) estimates
[3] Schaub et al (2018) *Cell Syst* PMID: 29596783
[4] Volpe et al. (2022) *Clin Lymphoa Myelom Leuk*, PMID: 34544674

Gyre THERAPEUTICS

Clinical Development of CG009301 in Patients with Recurrent or Refractory Hematologic Malignancies



- Dose escalation stage currently underway
- Data from first 8 patients demonstrated no observed DLTs
- Anticipate enrollment of approximately 30 – 45 patients

Gyre THERAPEUTICS

* Subject to regulatory alignment

Summary of CG009301 for Cancer

1 Positioning and Differentiation	• Relapsed / refractory AML, HR-MDS, and ALL patients • Potential to also treat relapsed / refractory MYC-driven solid tumors • Pre-clinical leukemia models indicate strong anti-tumor activity
2 Clinical Strategy	• Cullgen initiated a Phase 1 clinical trial in subjects with refractory hematologic malignancies in April 2025 in China. The expansion cohorts will focus on R/R AML, HR-MDS and ALL patients with hopes of identifying the optimal cohort for subsequent Phase 2 testing.
3 Clinical Development Plan	• The Phase 1a/1b data is expected to be submitted as the basis for an IND application to conduct the Phase 2 studies in the chosen disease population

Degrader-Antibody Conjugates (DACs)

Degrader-Antibody Conjugates (DACs) Are the Next-Generation of ADCs

TPD
(Targeted protein degradation)



+

ADC
(Antibody drug conjugate)

→

DAC
(Degrader antibody conjugate)



Modality	ADCs	TPD	DAC
Mechanism of Delivery	Intravenous	Oral or IV	Intravenous
Payload	Indiscriminate	**Tumor target selective**	**Target selective**
Efficacy	Requires potent payload	**Catalytic & potent**	**Catalytic & potent**
Tumor Selective Delivery	**Tumor cell selective**	Depends on E3	**Tumor cell selective**
Ability to Reduce Off Target Toxicity	No	Depends on E3	Yes
Need for oral bio-availability or cell permeability optimization	No	Yes	No

DAC Mechanism of Action Overview



HIGH POTENCY

The catalytic mechanism of action of TPDs ensures small quantity of degrader delivered by the antibody to achieve sufficient efficacy.

IMPROVED PK

Extended half-life, reduced systemic clearance, improved solubility, and bypassing the need for oral bio-availability or cell permeability optimization.

IMPROVED SAFETY

Reduced toxicity through dual target selectivity at the cell surface (antibody-tumor associated antigen) and intracellularly (degrader-target protein).

Epigenetic Factor DAC Demonstrates Potent and TAA-dependent Target Degradation and Cell Killing

A. Cullgen epigenetic factor DAC induces potent protein target degradation in a TAA-dependent manner *in vitro*

Cell Line	TAA Positive Cell Line																	
Compounds (nM)	DMSO	Degrader					DAC					DMSO	Linker-degrader					DMSO
		0.01	0.1	1	10	100	0.01	0.1	1	10	100		0.01	0.1	1	10	100	
Lane	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18



Cell Line	TAA Negative Cell Line																		
Compounds (nM)	DMSO	Degrader					DAC					DMSO	Linker-degrader					mAb		DMSO
		0.01	0.1	1	10	100	0.01	0.1	1	10	100		0.01	0.1	1	10	100	10	100	
Lane	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20



B. Cullgen epigenetic factor DAC kills cancer cells in a TAA-dependent manner





Gyre THERAPEUTICS

Degrader-Antibody Conjugates: Durable Tumor Regression, Superior to Dxd-ADC, and Overcoming Resistance in CDX and PDX Animal Models

A. DACs exhibit durable tumor growth inhibition in various solid tumor models

VCaP Prostate Cancer CDX model



HCC827 NSCLC CDX model



MDA-MB-453 Breast Cancer Model



NCI-N87 Grastric Cancer CDX Model



B. DACs are more effective than Dxd-based ADCs

BT474 Breast Cacner CDX model



C. DACs are effective in a CRPC PDX model resistant to enzalutamide



Gyre THERAPEUTICS

Gyre Has Established a Robust DAC Platform

DACs represent the next generation of ADC therapies

Cullgen has developed >7,000 active degraders targeting >20 distinct proteins, serving as a valuable resource for payload selection

We have successfully generated multiple DACs and demonstrated their selectivity, efficacy and safety

Conjugating a diverse array of degraders to different antibodies offers the opportunity to selectively target different cancer types



Gyre THERAPEUTICS

U.S. Management Team with Cross-Culture Operational Experience

Ying Luo, Ph.D.
Chief Executive Officer

Thomas Eastling
Chief Financial Officer

Weiguo Ye
Chief Operating Officer

Yue Xiong, Ph.D.
Chief Scientific Officer

Jialiang Wang, Ph.D.
Executive Vice President, General Manager

Joshua Bergmann, J.D.
General Counsel and Corporate Secretary

Ruoyu Chen
Chief Information Officer

Seth Goldblum, MBA
Senior Vice President - Corporate Development

Jing Liu, Ph.D.
Senior Vice President – Platform Chemistry

Mark Marino, M.D.
Senior Vice President – Clinical Development

Michael Plewe, Ph.D.
Senior Vice President - Medicinal Chemistry

Leslie Robinson, Ph.D., J.D.
Vice President - Intellectual Property and Licensing

Liang Zhao
VP Corporate Controller

Key Value Drivers

1. Robust and balanced therapeutic pipeline including assets from discovery to marketed products, with established manufacturing and commercialization operations
2. Utilization of highly efficient and cost-effective drug discovery and innovation capabilities in China to advance risk-mitigated products to the United States
3. Strong foundation in protein degrader development provides distinct advantage for the development of DACs as next generation ADC therapeutics
4. Accomplished management team in the United States and China with extensive international business operations experience

Thank You!

Gyre THERAPEUTICS